Press releases
-
-
Internal link ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
-
Internal link ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
-
-
-
-
Internal link ProQR Announces Annual Meeting of Shareholders
-
-
-
Internal link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
-
Internal link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
-
-
-
-
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR to Present at Upcoming Scientific Conferences
-
Internal link ProQR to Present at Upcoming Investor Conferences
-
-
-
-
-
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
-
Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10
-
Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients